GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:09 2024-06-14 EDT			5-day change	1st Jan Change
1,604 ^GBX	-0.34%		-1.50%	+10.64%

06-13	REGENXBIO Inc. Announces Chief Executive Officer Changes	CI
06-12	Moderna's RSV Vaccine Has 'Ample Opportunity' Despite Seasoned Competitors, Oppenheimer Says	MT

GSK: to present its advances in oncology at ASCO

May 24, 2024 at 04:20 am

GSK has announced that results from its oncology portfolio will be presented via 25 abstracts at the American Society of Clinical Oncology (ASCO) 2024 annual meeting.

In particular, data from the phase III DREAMM-8 and DREAMM-7 trials of belantamab mafodotin in combination to treat multiple myeloma after a first relapse will be presented.

Collaborations will also be highlighted, such as updated results for dostarlimab in dMMR rectal cancer, a phase II study of HS-20093 in Chinese patients with refractory osteosarcoma, and a phase 0/II trial of niraparib in unmethylated MGMT glioblastoma.

Copyright (c) 2024 CercleFinance.com. All rights reserved.

Go to the original article.
Legal disclaimer

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	GSK PLC	1,604 GBX	-0.34%	-1.50%	82.98B
	HS HOLDINGS CO., LTD.	949 JPY	+0.53%	+1.17%	182M

Latest news about GSK plc

REGENXBIO Inc. Announces Chief Executive Officer Changes	06-13	CI
Moderna's RSV Vaccine Has 'Ample Opportunity' Despite Seasoned Competitors, Oppenheimer Says	06-12	MT
GSK: licensing agreement with Ochre Bio	06-12	CF
Health Care Down as Rally Pauses -- Health Care Roundup	06-11	DJ
British Shares Extend Stay in Red Amid Signs of Job Market Cooling	06-11	MT
Global markets live: GSK, Tesla, Intel, General Motors, Gamestop...	06-11
Myriad Genetics, GSK Partner to Expand Access to HRD Diagnostic Testing	06-11	MT
GSK Starts Appeal Against US State Court Ruling on Zantac Lawsuit	06-11	MT
GSK Starts Appeal Process Against Delaware Court Decision Allowing Expert Testimonies in Zantac Litigation	06-11	MT
GSK Says Individual Plaintiff in Latest Zantac Case Dropped Claim -- Update	06-11	DJ
GSK takes first steps to appeal Zantac ruling in Delaware	06-11	AN
FTSE 100 up; UK unemployment rises to 4.4%	06-11	AN
GSK: decisions in the Zantac (ranitidine) litigation	06-11	CF
FTSE 100 called up despite unemployment rise	06-11	AN
GSK Appeals US Judge's Decision to Allow Plaintiff Expert Testimony in Zantac Litigation	06-11	MT
UK Stocks-Factors to watch on June 11	06-11	RE
GSK Says Individual Plaintiff in Latest Zantac Case Dropped Claim	06-11	DJ
GSK Files Application Seeking Right Of Appeal To Delaware Supreme Court On Zantac Litigation	06-11	RE
GSK Sees Dismissal of US Zantac Case Without Settlement	06-11	MT
Latest trial over Zantac cancer claims called off as plaintiff drops case	06-10	RE
GSK welcomes dismissal of Zantac case in Illinois	06-10	AN
Gsk PLC - Statement Zantac (Ranitidine) Litigation	06-10	RE
GSK Says FDA Approved RSV Vaccine's Expanded Age Indication	06-10	MT
Moderna COVID/flu combo vaccine superior to separate shots in trial	06-10	RE
GSK plc Announces That the US Food and Drug Administration Has Approved Arexvy	06-10	CI

Chart GSK plc

Duration

Period

More charts

Company Profile

GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Sector

Pharmaceuticals

Calendar

2024-06-17 - Analyst Meeting - Getting Ahead of Cancer

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

GSK PLC : Frightened markets create an entry opportunity in GSK

June 04, 2024 at 08:38 am

GSK plc : Back on track

May 03, 2024 at 05:17 am

More Strategies

Ratings for GSK plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

16.04 GBP

Average target price

20.36 GBP

Spread / Average Target

+26.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GSK PLC	+10.64%	82.98B
NOVO NORDISK A/S	+41.96%	630B
JOHNSON & JOHNSON	-7.15%	350B
MERCK & CO., INC.	+18.77%	328B
ABBVIE INC.	+8.79%	298B
ASTRAZENECA PLC	+18.02%	246B
ROCHE HOLDING AG	+1.27%	225B
NOVARTIS AG	+11.95%	218B
AMGEN INC.	+3.68%	160B
PFIZER, INC.	-4.38%	156B

Other Pharmaceuticals

GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

GSK: to present its advances in oncology at ASCO

Stocks mentioned in the article

EPS Revisions